Characteristic | PMA | NMA |
---|---|---|
Number of studies | 4 (3 to 25) | 14 (4 to 104) |
Randomised sample | 60 (4 to 1996) | 247 (12 to 18201) |
Number of interventions | 2 | 6 (3 to 22) |
Observed comparisons (%) | 1 | 42 (13 to 100a) |
Εvent frequency (%) in study-arms (binary outcomes only) | 47 (26 to 67)b | 60 (42 to 76)b |
Studies with at least one zero-cell (binary outcomes only) | 2 (1 to 6) [33] | 1 (1 to 4)[9] |
Intervention-comparison type: | Â | Â |
 Pharma versus placeboc | 37 (34) | 23 (68) |
 Pharma versus pharmac | 46 (43) | 9 (26) |
 Non-pharmad versus pharmac | 3 (3) | 1 (3) |
 Non-pharma versus non-pharmac | 22 (20) | 1 (3) |
Proportion of studies associated with: | Â | Â |
 Low risk of bias due to MODe | 33 (8 to 100) [6]f | 50 (6 to 100) [3]f |
 Moderate risk of bias due to MODe | 33 (10 to 100) [2]f | 44 (7 to 92) |
 High risk of bias due to MODe | 55 (11 to 100) [9]f | 28 (4 to 80) |